Fibrin-PTH – the first drug-biologic combination for interbody spinal fusions, currently undergoing a Phase 2 clinical trial in the US. How did the company come about? Kuros was formed in 2017, through the merger of Kuros Biosurgery AG and Xpand Biotechnology BV. Kuros Biosurgery was created as a spin-off from the prestigious ETH institute in Zurich, where Jeff Hubbell, a leading researcher in the field of biomaterials, and his team developed the proprietary TG hook peptide linker technology that underpins the current Fibrin PTH clinical development program. The roots of Xpand Biotechnology originated more than 30 years ago when I began developing calcium phosphate bone grafts. Since then, I’ve been responsible for the development of products sold by IsoTis, Integra Life Sciences, SeaSpine, NuVasive - and most recently by Kuros itself. MagnetOs is the latest in a long line of calciumphosphate bone grafts developed by the teamat Kuros – and features the unique NeedleGrip surface technology. Over a decade ago, our scientists discovered that calcium phosphates could form bone in soft tissues without added cells or growth factors. Using the latest research techniques, the team then made a vital discovery: that the proprietary submicron needle shaped features of the NeedleGrip surface could modulate immune cell polarisation in favour fof a pro healing response - thus unlocking previously untapped potential to stimulate stem cells and form bone through the graft. MagnetOs has been on the market in the EU since 2017 and in the US since 2018. Joost de Bruijn “Over a decade ago, our scientists discovered that calcium phosphates could form bone in soft tissues without added cells or growth factors. THE CEO INTERVIEW
RkJQdWJsaXNoZXIy Mjk3Mzkz